Details of the Drug Reposition

General Information of This Drug (ID: DMTBFXW)

Drug Name
CART 19   DMTBFXW
Drug Type
CAR T Cell Therapy

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
1 Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Acute lymphoblastic leukaemia DIS87TGM 2A85 Phase 2 [1]
------------------------------------------------------------------------------------
1 Preclinical Indication(s)
Indication Name Indication ID ICD-11 Status REF
Pancreatic cancer DISJC981 2C10 Preclinical [2]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT02935543) CART19 in Adult Patients With Minimal Residual Disease During Upfront Treatment for ALL
2 ClinicalTrials.gov (NCT02640209) Pilot Trial Of Autologous T Cells Engineered To Express Anti-CD19 Chimeric Antigen Receptor (CART19)In Combination With Ibrutinib In Patients With Relapsed Or Refractory CD19+ Chronic Lymphocytic Leukemia (CLL)Or Small Lymphocytic Lymphoma (SLL)